VISTN.OL
Vistin Pharma ASA
Price:  
25.70 
NOK
Volume:  
1,978,079.00
Norway | Pharmaceuticals
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

VISTN.OL WACC - Weighted Average Cost of Capital

The WACC of Vistin Pharma ASA (VISTN.OL) is 6.4%.

The Cost of Equity of Vistin Pharma ASA (VISTN.OL) is 6.55%.
The Cost of Debt of Vistin Pharma ASA (VISTN.OL) is 4.25%.

Range Selected
Cost of equity 5.40% - 7.70% 6.55%
Tax rate 22.00% - 22.10% 22.05%
Cost of debt 4.00% - 4.50% 4.25%
WACC 5.3% - 7.5% 6.4%
WACC

VISTN.OL WACC calculation

Category Low High
Long-term bond rate 3.3% 3.8%
Equity market risk premium 5.1% 6.1%
Adjusted beta 0.41 0.55
Additional risk adjustments 0.0% 0.5%
Cost of equity 5.40% 7.70%
Tax rate 22.00% 22.10%
Debt/Equity ratio 0.05 0.05
Cost of debt 4.00% 4.50%
After-tax WACC 5.3% 7.5%
Selected WACC 6.4%

VISTN.OL's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for VISTN.OL:

cost_of_equity (6.55%) = risk_free_rate (3.55%) + equity_risk_premium (5.60%) * adjusted_beta (0.41) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.